XERS - Company ID 0001867096
The table below shows Xeris Biopharma Holdings, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $111.75M | $91.60M | $59.28M | $58.44M | $59.23M | $57.60M |
| Short-term investments | - | - | - | - | $10.17M | $19.96M |
| Receivables | $56.30M | $53.75M | $53.05M | $46.33M | $41.14M | $42.44M |
| Inventory | $74.23M | $67.46M | $67.28M | $52.69M | $45.12M | $42.98M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $251.68M |
| $224.02M |
| $185.58M |
| $163.49M |
| $162.80M |
| $170.34M |
| Property, plant & equipment | $5.03M | $4.95M | $5.28M | $5.26M | $5.61M | $5.83M |
| Goodwill | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M |
| Total assets | $392.01M | $370.19M | $334.69M | $315.45M | $321.10M | $331.73M |
| Accounts payable | $11.47M | $6.53M | $9.46M | $6.35M | $7.45M | $5.80M |
| Total current liabilities | $118.59M | $116.20M | $95.17M | $95.07M | $91.01M | $75.49M |
| Long-term debt | $221.22M | $219.47M | $218.63M | $217.81M | $216.23M | $230.48M |
| Total liabilities | $379.00M | $371.05M | $353.99M | $350.58M | $349.43M | $351.02M |
| Retained earnings | -$669.07M | -$682.39M | -$683.01M | -$681.08M | -$666.75M | -$651.01M |
| Total equity | $13.01M | -$861.00K | -$19.30M | -$35.13M | -$28.32M | -$19.29M |